Is Avidity Biosciences, Inc. (RNAM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 15.1% / 30% | 0.1% / 30% | 337.27% / 5% | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 15.1% / 33% | 0.1% / 33% | 337.27% / 5% | ✗ NOT HALAL |
| MSCI | 2.5% / 33% | 86.7% / 33% | 0.6% / 33% | 337.27% / 5% | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 15.1% / 33% | 0.1% / 33% | 337.27% / 5% | ✗ NOT HALAL |
| FTSE | 2.5% / 33% | 86.7% / 33% | 0.6% / 50% | 337.27% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -29590.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -44.0% | |
| Return on Assets (ROA) | -26.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$650M |
| Free Cash Flow | -$668M |
| Total Debt | $49M |
| Debt-to-Equity | 2.9 |
| Current Ratio | 9.2 |
| Total Assets | $2.0B |
Price & Trading
| Last Close | $0.00 |
| 50-Day MA | $72.33 |
| 200-Day MA | $54.38 |
| Avg Volume | 1.9M |
| Beta | 0.9 |
|
52-Week Range
$21.51
| |
About Avidity Biosciences, Inc. (RNAM)
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. As of February 27, 2026, Avidity Biosciences, Inc. operates as a subsidiary of Novartis AG.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Avidity Biosciences, Inc. (RNAM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Avidity Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Avidity Biosciences, Inc.'s debt ratio?
Avidity Biosciences, Inc.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.5%.
What are Avidity Biosciences, Inc.'s key financial metrics?
Avidity Biosciences, Inc. has a market capitalization of $11.2B, and revenue of $19M. Return on equity stands at -44.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.